BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

9478	Companies
185492	Keywords
117871	Articles
99349	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 08/20/2025 at 09:05, 3 months 16 days ago

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
BioNxt announces fast-tracked U.S. patent filing for BNT23001 sublingual thin-film cladribine formulation targeting neurological autoimmune disorders. Broad international patent core claims accepted for platform-level protection

Autoimmune Diseases Drug Delivery Neurological Disorders Patent Filing BioNxt
BRIEF

published on 08/09/2025 at 01:05, 3 months 27 days ago

BioNxt Solutions Completes Oversubscribed Convertible Debenture Offering

Private Placement Convertible Debenture Warrants Product Development BioNxt Solutions
BRIEF

published on 08/09/2025 at 01:05, 3 months 27 days ago

BioNxt Solutions finalise son offre d'obligations convertibles sursouscrite

Placement Privé Développement De Produits Mandats Obligation Convertible Solutions BioNxt
PRESS RELEASE

published on 08/09/2025 at 01:00, 3 months 27 days ago

BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising $241,200 for convertible debentures and issuing Warrants. Funds intended for product development and IP filings

Private Placement Warrants Convertible Debentures BioNxt Solutions Inc. Product Development
BRIEF

published on 08/05/2025 at 09:10, 4 months ago

BioNxt Solutions Advances Patent Protection for MS Treatment

Multiple Sclerosis Drug Delivery Technology Patent Protection BioNxt Solutions Sublingual Cladribine
BRIEF

published on 08/05/2025 at 09:10, 4 months ago

BioNxt Solutions renforce la protection des brevets pour le traitement de la sclérose en plaques

Sclérose En Plaques Technologie D'administration De Médicaments Solutions BioNxt Cladribine Sublinguale Protection Par Brevet
PRESS RELEASE

published on 08/05/2025 at 09:05, 4 months ago

BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
BioNxt Solutions Inc. makes significant progress in global patent portfolio with EPO and EAPO confirming acceptance of core claims for sublingual Cladribine thin-film formulation. Focus on innovation in MS treatment

BioNxt Solutions Inc. Patent Portfolio Cladribine EPO EAPO
BRIEF

published on 07/26/2025 at 00:05, 4 months 10 days ago

BioNxt Solutions clôture la première tranche de son placement d'obligations

Obligations Convertibles Placement Privé Développement De Produits Mandats Solutions BioNxt
BRIEF

published on 07/26/2025 at 00:05, 4 months 10 days ago

BioNxt Solutions Closes First Tranche of Debenture Placement

Private Placement Warrants Convertible Debentures Product Development BioNxt Solutions
PRESS RELEASE

published on 07/26/2025 at 00:00, 4 months 10 days ago

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes first tranche of non-brokered private placement, raising $1,009,200 for drug delivery tech and IP development. Securities subject to statutory hold until Nov 26, 2025

Private Placement Convertible Debentures BioNxt Solutions Inc. Intellectual Property Drug Delivery Technologies

Accesswire

Published on 12/05/2025 at 16:00, 42 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 57 minutes ago

Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 57 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 1 hour 7 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour 17 minutes ago

Usha Resources Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 16:25, 17 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 32 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 42 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 42 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 42 minutes ago

Amundi Physical Metals plc: Communiqué de Mise à Disposition du Rapport Financier Semestriel au 30 septembre 2025

Les Echos

Published on 12/05/2025 at 15:10, 1 hour 31 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 1 hour 31 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 2 hours 44 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 7 hours 57 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 7 hours 57 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE